— Know what they know.
Not Investment Advice

ELVN NASDAQ

Enliven Therapeutics, Inc.
1W: -1.9% 1M: -4.9% 3M: +62.4% YTD: +171.9% 1Y: +143.1% 3Y: +113.2% 5Y: +31.2%
$41.54
-0.71 (-1.68%)
 
Weekly Expected Move ±6.0%
$36 $39 $41 $44 $46
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 45 · $2.5B mcap · 35M float · 3.08% daily turnover · Short 61% of daily vol

📊 Key Metrics

TTM
$0M
Revenue
+0.0% YoY
$-99M
Net Income
-4.2% YoY
$-66M
Free Cash Flow
+11.3% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-25.7%
ROA-24.6%
ROIC3488.7%

Valuation

P/E-26.4
P/B5.8
EV/EBITDA-18.1

Leverage

Debt/Equity0.00
Current Ratio28.66
Interest Cov.0.0x

Quality Scores

Piotroski F4/9
Altman Z87.94
Beneish M0.00

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms